Actively Recruiting
Characterization of Bacterial and Mycosis Skin Flora in Seborrheic Macular Hypopigmentation - Microbiome
Led by Centre Hospitalier Universitaire de Nice · Updated on 2025-07-01
20
Participants Needed
3
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Hypopigmented skin changes are commonly encountered by dermatologists. A new dermatological entity was identified as scattered, hypopigmented oval-shaped macules and patches distributed mostly in seborrheic area of the face and of the trunk in dark skinned individuals. This patterned presentation of hypopigmentation was first described in the literature under the name of hypochromic vitiligo or vitiligo minor. Nerveless, histopathological patient's specimens analyzed by Krueger et al. clearly highlight that there is no tangible causal correlation with a diagnosis of vitiligo. They propose to rename this entity to Seborrheic Macular Hypopigmentation (SMH). The etiopathology of this dermatosis is still unknown preventing to propose any satisfactory treatment for this disfiguring affection.The objective of this study is to analyze the bacterial and fungal skin microbiome on hypochromic lesions of SMH compared to the surrounding non-lesional skin of the same patients and to healthy volunteers
CONDITIONS
Official Title
Characterization of Bacterial and Mycosis Skin Flora in Seborrheic Macular Hypopigmentation - Microbiome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female and male patients 18 years of age or older
- Clinical diagnosis of SMH with lesion on the face
- Written informed consent obtained before any assessment
- Affiliation with a social security scheme
- Physical and psychological ability to participate
You will not qualify if you...
- Use of systemic antibiotics or systemic antifungal treatments within 4 weeks before the inclusion visit
- Use of topical antibiotics or topical antifungal treatments on the face within 2 weeks before the inclusion visit
- Use of any topical cream, gel, serum, or ointment within 2 days before the inclusion visit
- Laser, radiofrequency, peeling, or any other procedure on the face in the past 3 months before the inclusion visit
- Vulnerable patients including minors, patients under guardianship or curatorship, pregnant or breast-feeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
CHU de Nice - Hôpital de l'Archet
Nice, Alpes-Maritimes, France, 06200
Actively Recruiting
2
Hôpital Louis Pasteur, hôpitaux Civils de Colmar
Colmar, Colmar, France, 68024
Actively Recruiting
3
Hôpital Saint-Louis - APHP
Paris, Île-de-France Region, France, 75010
Actively Recruiting
Research Team
T
Thierry Passeron, PhD
CONTACT
E
emmanuelle PRADELLI
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here